These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Introduction to special section: biologic agents in the treatment of rheumatic diseases-the first decade. Yelin E; Katz P Arthritis Rheum; 2009 May; 61(5):559. PubMed ID: 19405010 [No Abstract] [Full Text] [Related]
28. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? Haraoui B J Rheumatol; 2004 Jun; 31(6):1021-2. PubMed ID: 15170907 [No Abstract] [Full Text] [Related]
29. [Pregnancy in rheumatic patients treated with biologic drugs]. Sentić M; Baresić M; Anić B; Bosnić D; Cerovec M; Mayer M; Smiljanić L; Cikes N Lijec Vjesn; 2010; 132(9-10):317-8. PubMed ID: 21261033 [No Abstract] [Full Text] [Related]
30. [Tolerance of anti-TNF alpha: the experience acquired in inflammatory rheumatic disease]. Mariette X Ann Dermatol Venereol; 2006 May; 133(5 Pt 2):1S8-12. PubMed ID: 16967603 [No Abstract] [Full Text] [Related]
31. [TNF-alpha antagonists in therapy of rheumatoid arthritis]. Gross WL; Gause A Z Rheumatol; 2003 Jun; 62(3):217. PubMed ID: 12931691 [No Abstract] [Full Text] [Related]
32. New therapies for rheumatoid arthritis. Goldblatt F; Isenberg DA Clin Exp Immunol; 2005 May; 140(2):195-204. PubMed ID: 15807842 [TBL] [Abstract][Full Text] [Related]
34. Anti-tumour necrosis factor agents and lipid profile: a class effect? Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660 [No Abstract] [Full Text] [Related]
35. [Non-TNF biologicals in therapy]. Wollenhaupt J; Burmester GR Z Rheumatol; 2010 Sep; 69(7):579-80. PubMed ID: 20703491 [No Abstract] [Full Text] [Related]
36. TNF antagonists and shingles: is vaccination advisable? Nisar MK; Ostor AJ Ann Rheum Dis; 2013 May; 72(5):e1. PubMed ID: 23456927 [No Abstract] [Full Text] [Related]
37. New cytokine targets in inflammatory rheumatic diseases. Connell L; McInnes IB Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):865-78. PubMed ID: 16980211 [TBL] [Abstract][Full Text] [Related]
38. Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy? Winger EE; Reed JL J Rheumatol; 2009 Sep; 36(9):2122; author reply 2123. PubMed ID: 19738224 [No Abstract] [Full Text] [Related]
39. The application of infliximab (Remicade), a chimeric monoclonal antibody, in the treatment of rheumatic diseases. Kalden JR Isr Med Assoc J; 2000 Dec; 2 Suppl():11-2. PubMed ID: 11344856 [No Abstract] [Full Text] [Related]
40. Review: basics of drug development in rheumatology. Mina-Osorio P Arthritis Rheumatol; 2015 Oct; 67(10):2581-90. PubMed ID: 26138901 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]